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Background/Aims
There has been major progress in our understanding of the irritable bowel syndrome (IBS), and novel treatment classes have emerged. 
The Rome IV guidelines were published in 2016 and together with the growing body of Asian data on IBS, we felt it is timely to 
update the Asian IBS Consensus.
Methods
Key opinion leaders from Asian countries were organized into 4 teams to review 4 themes: symptoms and epidemiology, 
pathophysiology, diagnosis and investigations, and lifestyle modifications and treatments. The consensus development process was 
carried out by using a modified Delphi method.
Results
Thirty-seven statements were developed. Asian data substantiate the current global viewpoint that IBS is a disorder of gut-brain 
interaction. Socio-cultural and environmental factors in Asia appear to influence the greater overlap between IBS and upper 
gastrointestinal symptoms. New classes of treatments comprising low fermentable oligo-, di-, monosacharides, and polyols diet, 
probiotics, non-absorbable antibiotics, and secretagogues have good evidence base for their efficacy.
Conclusions
Our consensus is that all patients with functional gastrointestinal disorders should be evaluated comprehensively with a view to 
holistic management. Physicians should be encouraged to take a positive attitude to the treatment outcomes for IBS patients.
(J Neurogastroenterol Motil 2019;25:343-362)
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Introduction  
The first Asian Consensus on Irritable Bowel Syndrome (IBS) 
was published in 2010.1 Since then, there has been major progress 
in our understanding of this condition and novel treatment classes 
have emerged. The international standard for diagnostic criteria in 
functional gastrointestinal disorders (FGIDs) was updated with the 
release of the Rome IV documents in 2016.2 FGIDs are now de-
scribed as disorders of gut-brain interaction, shifting the emphasis 
to the gut, with greater prominence given to the intestinal micro-
environment. Furthermore, there is now recognition of the roles 
of cross-cultural differences, the socio-cultural and environmental 
factors in the development and manifestation of IBS. The Asian 
Neurogastroenterology and Motility Association (ANMA) felt it is 
appropriate to examine the literature from an Asian perspective and 
to update the Asian IBS Consensus.
Methods  
On April 1, 2016, ANMA convened a working team of 21 key 
opinion leaders from Asian countries on the basis of their scientific 
activities and published articles on IBS. Participants were organized 
into 4 teams to review 4 themes: symptoms and epidemiology, 
pathophysiology, diagnosis and investigations, and lifestyle modi-
fications and treatments. The consensus development process was 
carried out by using a modified Delphi method.3
The consensus team members collected and reviewed original 
publications on IBS (in English and other languages) since the first 
consensus, through available global and domestic online literature-
search systems. Manual search was also performed for publications 
that were not available online. Other important original and review 
articles from Asia and other parts of the world were also collected 
and reviewed. New publications that were published during the 
consensus process were also reviewed. Each team then generated 
6 to 12 consensus statements through intra- and inter-team e-mail 
discussions.
On March 22, 2017, the working team met in Osaka during 
the ANMA Scientific Congress. All statements were presented 
along with supporting evidence, debated, and modified based on 
feedback. A grade of evidence was applied to every statement ac-
cording to the GRADE Working Group.4 The final complete 
set of statements was subsequently circulated to all 21 members 
for anonymous voting. All members were asked to choose 1 of 
the following 6 levels of agreement on each statement: (a) accept 
completely, (b) accept with minor reservation, (c) accept with major 
reservation, (d) reject with major reservation, (e) reject with minor 
reservation, and (f) reject completely. The members were also asked 
to provide comments to each statement, if any. When the propor-
tion of members who voted (a) or (b) was greater than or equal to 
80.0%, the statement was regarded as acceptable and a consensus 
was considered to have been reached.
Team 1: Symptoms and Epidemiology  
Statement 1: Bowel-related symptoms in IBS consist of abdomi-
nal pain, bloating, or discomfort that is either improved or aggravat-
ed by passing stool or flatus. The symptoms can be associated with 
change in stool form or frequency and other symptoms including 
urgency, straining, and feeling of incomplete defecation.
Grade of evidence: moderate
 Level of agreement: a. 80.9%; b. 0.0%; c. 14.3%; d. 0.0%; 
e. 4.8%; f. 0.0%
These characteristics of IBS symptoms are derived from the 
original studies by Manning and by Thompson.5,6 In the subse-
quent diagnostic criteria for IBS (Rome I to III), abdominal pain 
and/or discomfort are important components in the evaluation. 
In the Rome IV era, the term “discomfort” has been eliminated 
from the criteria because the term is thought to be ambiguous to 
patients.7 The current Rome IV definition for IBS required the 
patients to have recurrent abdominal pain, which is associated with 
defecation or a change in bowel habits. However, a recent global 
experts survey indicated that 53.8% felt that bloating was the most 
important feature of IBS, while only 25.6% felt that abdominal 
pain was.8 A study from China by using Rome III defined IBS, 
only 64.6% of them complained of recurrent abdominal pain and 
44.2% with abdominal bloating alone.9 A large population-based 
internet survey from Japan also suggests that abdominal bloating 
has a great impact on the daily life of the patients with constipation-
predominant IBS.10 Studies of IBS patients in India and Bangla-
desh suggested that frequency and/or severity of abdominal pain 
may not be so common, ranging from 33.0% to 70.0%, which will 
result in a low prevalence of Rome IV IBS in India.11 In a multi-
center Indian study using various IBS diagnostic criteria, the Man-
ning criteria had the highest sensitivity (91.0%), followed by Asian 
criteria (74.5%), Rome  I (68.0%), Rome III (52.5%), and Rome II 
(40.0%) to diagnose IBS.12 The differences observed may be due 
to the fact that “abdominal pain” was not absolutely necessary for 
the diagnosis of IBS by both Manning and Asian criteria. Further-
more, “abdominal bloating” had been included in combination with 
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“abdominal pain or discomfort” by the Asian criteria.1 Similar data 
has been reported from Romania.13 These data suggested that be-
sides recurrent abdominal pain, abdominal bloating should also be 
included in the IBS diagnostic criteria, while the pain component in 
IBS may be de-emphasized in Asia.
Since the words for bloating symptom in several Asian coun-
tries have meanings overlapping with other abdominal symptoms, 
doctors in these countries should explore in detail to confirm wheth-
er the patient symptom is a real bloating symptom or not, according 
to the symptom concept described by the Rome committee.
Statement 2: The patient's bowel pattern should be described 
according to the Bristol stool form scale (BSFS) with consideration 
to stool frequency, straining, incomplete evacuation, and urgency.
Grade of evidence: moderate
 Level of agreement: a. 71.4%; b. 19.1%; c. 9.5%; d. 0.0%; 
e. 0%; f. 0.0%
According to Western studies, stool frequency of normal bowel 
habit varies from 3 stools per week to 3 per day.14 However, wide 
variation in normal bowel frequency is noted throughout Asian 
countries. For example, normal stool frequency is once per day in 
Chinese and twice per day in Iranians.15,16 In Indian community, 
90.0% of healthy subjects had more than 1 bowel movement per 
day, less than 1.0% had number of bowel movement fewer than 
3 per week, while the median stool frequency was twice a day in 
IBS patients, regardless of whether they had constipation or diar-
rhea.17 It has consistently being shown that stool form rather than 
stool frequency better represent colonic transit time.18,19 Therefore, 
evaluating stool form using the Bristol scale is suggested as the tool 
of choice in the classification of IBS subtypes in Asia. Bristol stool 
scale has been reported to be a better marker of constipation and 
slow colonic transit.19-21 A recent validation study has also shown 
that IBS patients could more often be classified as having constipa-
tion- or diarrhea-predominant bowel pattern by the Bristol stool 
form and by the patients' own perception than by the stool frequen-
cy criteria.22
Statement 3: IBS patients may complain of meal-related symp-
toms, which include abdominal pain, bloating or distension.
Grade of evidence: moderate
 Level of agreement: a. 76.1%; b. 14.3%; c. 4.8%; d. 4.8%; 
e. 0.0%; f. 0.0%
Several studies provide strong evidence that eating is an im-
portant trigger of symptoms in IBS patients.23-26 A study in Sweden 
required IBS patients to record in detail the timing of symptoms 
throughout the day for up to 6 weeks. This study demonstrated 
that pain was relieved with defecation on only 10.0% of occasions, 
whereas 50.0% of pain episodes developed within 90 minutes of eat-
ing.27 This study suggests that the pain experienced by IBS patients 
had a stronger temporal relationship to eating than to defecation. 
This could be a particular problem in Asia because Asian patients 
appear to present more frequently with upper abdominal pain than 
in Western patients.28,29 In a study from Taiwan, more than 50% 
of patients initially classified as dyspepsia were reclassified as IBS 
because their upper abdominal pain was exclusively relieved with 
defecation.30 We believe that it is important to highlight the relation-
ship of symptoms to meals in IBS. Mistaking meal-related IBS 
symptoms as dyspepsia could lead to excessive investigation with 
tests, such as upper gastrointestinal (GI) endoscopy and ultrasound 
scans, inappropriate treatments, such as acid suppression, and un-
necessary surgery, such as cholecystectomy.31,32
Statement 4: IBS is as prevalent in men as in women in most 
Asian countries.
Grade of evidence: moderate
 Level of agreement: a. 80.9%; b. 14.3%; c. 4.8%; d. 0.0%; 
e. 0.0%; f. 0.0%
Globally the prevalence of IBS in women is approximately 1.5- 
to 3-fold higher than those seen in men.33,34 In Western populations, 
women usually report more IBS symptoms than men, irrespective 
of the employed diagnostic criteria.35 However, if the IBS prevalence 
is stratified according to geographic region, no significant sex differ-
ence can be observed in South Asia, South America, and Africa.33 
In Asia, most studies showed no gender difference (female vs male 
in India: 7.9% vs 6.9%, 4.3% vs 4%, 3.2% vs 4.8%; Korea: 7.1% vs 
6.0%; Hong Kong: 6.6% vs 6.5%; Pakistan: 13.1% vs 13.4%; Tai-
wan: 21.8% vs 22.8%; Singapore: 7.8% vs 9.4%; Malaysia: 10.6% 
vs 10.5%; Japan: 6.5% vs 5.5%).28,36-38 Untill now, only 2 reports 
showed significantly higher IBS prevalence in females.39,40
Statement 5: Dyspeptic symptoms including upper abdominal 
pain are prevalent in Asian IBS patients, and may result in a misdi-
agnosis of FD.
Grade of evidence: moderate
 Level of agreement: a. 76.2%; b. 14.2%; c. 4.8%; d. 0.0%; 
e. 4.8%; f. 0.0%
In Asia the prevalence of dyspeptic symptoms in IBS patients 
has been variously reported (India 58.0%, China 25.0-64.0%, and 
South Korea 14.0%).41-44 Furthermore Asian patients tend to pres-
ent more with upper abdominal pain than Western patients. In a 
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Taiwan study, Lu et al initially classified more than 50.0% of their 
patients as dyspepsia who were later reclassified as IBS when their 
upper abdominal pain was exclusively relieved with defecation.30 
Similarly in a study performed in Singapore, 44.0% of patients who 
had functional chronic upper abdominal pain had IBS, while a later 
study demonstrated that more than 50.0% of IBS subjects localized 
their pain to the upper abdomen.45,46 
Population-based studies demonstrated that 3.5% to 4.5% 
of the general adult population in India and Bangladesh have 
dyspepsia-IBS overlap.47,48 A community-based survey carried out 
involving 3000 people in Bangladesh, including both rural and ur-
ban populations, demonstrated that 42.0% of FD subjects had IBS 
and 27.0% IBS subjects had FD.48 Bowel symptoms frequency 
scores were higher in IBS-FD than IBS alone.47,48 In a hospital 
based study of patients with FD from China, postprandial fullness 
was a predictor of overlapping IBS.43 In a large study from Japan, 
abdominal bloating appears to be the most bothersome symptom in 
IBS with constipation (IBS-C) patients.10 Correspondingly, early 
satiety, epigastric pain, and bloating were important factors associ-
ated with IBS-FD overlap syndrome in Bangladesh.48 Bloating is a 
commonly encountered symptom in Asian IBS patients, in keeping 
with observations from Western countries. The challenge is not to 
misclassify these patients as functional dyspeptics when they actu-
ally suffer from IBS. An alternative is to view them as a spectrum of 
functional bowel disorders, focusing treatment on the main symp-
toms, or using combination therapy for the myriad of symptoms.
Statement 6: Stress relates to the exacerbation of IBS.
Grade of evidence: moderate
 Level of agreement: a. 95.2%; b. 4.8%; c. 0.0%; d. 0.0%; e. 
0.0%; f. 0.0%
Experience of psychosocial stress and exacerbation of GI 
symptoms in IBS patients show higher correlation than that in 
healthy individuals.49 IBS patients show more exaggerated colonic 
motility in response to experimental stress than healthy subjects.50 
A meta-analysis showed that colorectal distension in IBS patient is 
more likely to activate the anterior cingulate cortex, amygdala, and 
midbrain, which are important brain regions for stress response, 
but deactivates the medial and lateral prefrontal cortex than healthy 
controls.51 Furthermore, the right dorsolateral prefrontal cortex in 
IBS patients was less activated than healthy controls when subjects 
were exposed to the situation with necessity of cognitive flexibility 
and stress-coping.52
Systematic review indicated that psychosocial stress likely al-
ters gut microbiota, increases mucosal permeability, motility, and 
induces visceral hyperalgesia in IBS patients.53-55 Systematic review 
of epidemiology supports psychosocial stress (adverse life events) 
as one of risk factors of post-infection IBS (PI-IBS).56 When the 
severity of IBS increases, the impact of psychological distress in IBS 
patients increases.57 The interaction between IBS and psychologi-
cal symptoms are bi-directional. In a 12-year prospective study, 
functional GI disorder including IBS and functional dyspepsia at 
onset were found to increase the risk of developing depression and 
anxiety, while. depressive or anxiety disorder was a risk factor for the 
development of IBS.58 A 1-year prospective study indicates that in 
the majority of patients it is likely that IBS leads to depression and 
anxiety than the other way around.59
Team 2: Pathophysiology  
Statement 7: IBS is a multi-dimensional disorder with a variable 
combination of gut dysbiosis, GI low grade inflammation, mucosal 
immune activation, increased gut permeability, food intolerance, GI 
dysmotility, visceral hypersensitivity, altered gut-brain interaction, 
genetic, and psychosocial factors.
Grade of evidence: moderate
 Level of agreement: a. 80.9%; b. 14.3%; c. 4.8%; d. 0.0%; 
e. 0.0%; f. 0.0%
It is now appreciated that multiple pathophysiological mecha-
nisms may operate in individual patients contributing to symptoms 
and their exacerbation, health care seeking behavior, and treatment 
response. The important role that the gut micro-environment plays 
in the pathophysiology has been increasingly recognized.60 In the 
recently published Rome IV guidelines, the term “functional” is 
de-emphasized, and FGIDs are now defined as “disorders of gut-
brain interaction.”2
Statement 8: Gut microbial dysbiosis is associated with IBS, es-
pecially IBS with predominant diarrhea (IBS-D).
Grade of evidence: moderate
 Level of agreement: a. 71.4%; b. 23.8%; c. 4.8%; d. 0.0%; 
e. 0.0%; f. 0.0%
Multiple case-control studies from Asia and elsewhere demon-
strated fecal microbial dysbiosis among patients with IBS as com-
pared to controls.61-63 Since a fecal sample might not be representa-
tive of the small bowel, a few studies assessed small bowel aspirate 
among patients with IBS as compared to controls and showed dys-
biosis even in the upper gut of patients with IBS.64 Multiple stud-
ies using quantitative upper gut aspirate culture and glucose and 
lactulose hydrogen breath tests also revealed occurrence of small 
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intestinal bacterial overgrowth (SIBO) more often among patients 
with IBS than healthy subjects.65 Moreover, multiple studies docu-
menting improvement in IBS symptoms following treatment with 
antibiotics including rifaximin also supports the role of gut dysbiosis 
in pathogenesis of IBS.66,67 Patients with IBS-D more often had 
SIBO than other sub-types of IBS.63,67 However, a few studies 
showed that methane production on lactulose hydrogen breath test 
is associated with constipation and its reduction with rifaximin ac-
celerates colon transit time and improves constipation suggesting 
role of gut microbial dysbiosis even in a subset of patients with IBS-
C.68,69
Statement 9: IBS is associated with immune activation, low 
grade gut inflammation, and increased gut permeability.
Grade of evidence: high
 Level of agreement: a. 71.4%; b. 28.6%; c. 0.0%; d. 0.0%; 
e. 0.0%; f. 0.0%
A large body of evidence supports the presence of immune 
activation, low grade inflammation, and increased gut permeability 
in the pathogenesis of IBS, particularly in PI-IBS and the diarrhea-
predominant sub-type.70-75 In a study from India, over-producer 
polymorphisms of IL-1 receptor antagonist (which controls inflam-
mation) were found to be infrequent and under-producers frequent 
among patients with IBS than controls.76 The same study also 
revealed patients with SIBO had higher duodenal mucosal levels 
of IL-1α and β and the latter correlated with looser stools (Bristol 
type VI) and bloating.76 Another recent Indian study showed that 
altered immune activation in response to dysbiotic microbiota may 
promote intestinal inflammation in a subset of IBS patients.77 A 
Chinese study showed that IL-10, an anti-inflammatory cytokine 
level in serum, was significantly lower in SIBO-positive than nega-
tive IBS patients.78 Nerve growth factor is known to mediate vis-
ceral hypersensitivity and gut mucosal barrier dysfunction through 
interactions with mast cells and sensory nerves. In a recent Chinese 
study, elevated mucosal nerve growth factor has been suggested to 
interact with mast cells and sensory nerve fibers, contributing to vis-
ceral hypersensitivity and impaired gut barrier function in IBS-D.79
Statement 10: GI infection predisposes to development of IBS.
Grade of evidence: high
 Level of agreement: a. 80.9%; b. 14.3%; c. 4.8%; d. 0.0%; 
e. 0.0%; f. 0.0%
More than half a century ago, Chaudhary and Truelove de-
scribed occurrence of IBS like syndrome following acute GI infec-
tion.80 Subsequently, Gwee et al81 reported that 27.0% of patients 
with acute gastroenteritis from Sheffield, England continued to have 
symptoms sufficient to fulfill the criteria for IBS for 6 months. Four 
studies on PI-IBS have been reported from Asia to date. In one 
cohort study from Beijing, China, the incidence of IBS by Rome II 
criteria among 295 patients following bacillary dysentery was 8.1% 
compared to 0.8% among controls.75 In a study from Seoul inves-
tigating an outbreak of Shigella infection among 181 health-care 
workers, the odds ratio of developing IBS was calculated to be 2.9 
at 1 year.82 A 3-year follow-up study from Korea showed that PI-
IBS may last for 3 years after onset.83 A recent study conducted in 
Bangladesh showed gastroenteritis patients developed PI-IBS and 
PI-FD more often than controls (16.5% vs 2.6% and 7.4% vs 0.6%, 
respectively).84 The same study also showed that 9.0% of patients 
developing Rome criteria-positive IBS after acute gastroenteritis 
actually developed post-infectious malabsorption syndrome (tropical 
sprue).
PI-IBS is defined as new development of IBS following acute 
infectious diarrhea, characterized by 2 of the followings, (1) diar-
rhea, (2) vomiting, (3) fever, and (4) positive stool culture for en-
teropathogens.85 PI-IBS is usually of diarrhoea-predominant sub-
type. In Asia, post-infective malabsorption, previously known as 
Tropical sprue, should be considered as a differential diagnosis.86 
SIBO has been proposed as a possible link between the 2 condi-
tions.85
Statement 11: Visceral hypersensitivity plays an important role 
in the development of symptoms in IBS patients.
Grade of evidence: moderate
 Level of agreement: a. 85.7%; b. 9.5%; c. 4.8%; d. 0.0%; e. 
0.0%; f. 0.0%
Exaggerated visceral sensitivity is well known in patients with 
IBS as compared to controls based on studies on luminal distension 
using balloon and gas during colonoscopy and lactose hydrogen 
breath test.87,88 Such luminal distension has also been shown to 
reproduce patient’s abdominal pain. Visceral hypersensitivity in 
patients with IBS spans beyond the colon. It has been demonstrated 
in the esophagus, stomach, duodenum, and ileum, suggesting that 
these patients have irritable gut syndrome.89 Studies from Asia, like 
those from the rest of the world, also demonstrated hypersensitiv-
ity beyond the gut such as bladder dysfunction and fibromyalgia 
among patients with IBS. In an Indian study, following 50 g lactose 
ingestion, IBS patients experienced symptoms more than healthy 
subjects though the amount of breath hydrogen exhaled was com-
parable between the 2 groups.89 A Chinese study also showed simi-
lar results.90 Another Chinese study demonstrated that cold water 
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intake lowered the visceral perception threshold.91 Abdominal pain 
could be elicited in 78.0% of patients with IBS in Singapore by dis-
tending the rectum with air insufflation.92
Statement 12: Dysregulated entero-endocrine system may con-
tribute to pathogenesis of IBS.
Grade of evidence: low
 Level of agreement: a. 80.9%; b. 4.8%; c. 14.3%; d. 0.0%; 
e. 0.0%; f. 0.0%
Evidence includes increased enterochromaffin cell numbers as 
well as rectal mucosal serotonin (5-hydroxytryptamine [5-HT]) in 
PI-IBS, presence of 5-HT-transporter-gene-linked polymorphic 
region mutation in IBS-C (in China and Korea), and altered seroto-
nergic signaling (increased and decreased plasma serotonin levels in 
IBS-D and IBS-C respectively).71,93-95 Of particular interest in Asia 
is the possible role that 5-HT3 receptors may play in chili induced 
abdominal symptoms associated with IBS.96 However, a recent 
study compared enterochromaffin cells numbers in the colon of IBS 
and controls from subjects in Norway and Thailand demonstrated 
increased enterochromaffin cell numbers in IBS patients compared 
to controls only in Norwegian patients but not in Thai patients.97
Statement 13: GI motility disturbances in IBS patients can 
arise from an exaggerated physiological response to environmental 
stimuli, such as meals and stressors.
Grade of evidence: high
 Level of agreement: a. 80.9%; b. 14.3%; c. 0.0%; d. 4.8%; 
e. 0.0%; f. 0.0%
Exaggerated gastro-colic reflex among patients with IBS is 
well known. In an American study, colonic spike and motor activity 
were higher following a meal among patients with IBS compared to 
healthy subjects.26 Diarrhea-predominant IBS patients have higher 
colonic motility than constipation-predominant subset. A Korean 
study showed that patients with diarrhea-predominant IBS showed 
higher colonic motility than those with constipation-predominant 
IBS.98 Lactose malabsorption are common among patients with 
IBS in Asia. An Indian study showed that though levels of breath 
hydrogen were comparable among patients with IBS and healthy 
controls, IBS patients showed greater frequency of symptom de-
velopment following lactose load than healthy subjects.88 This may 
be related to greater degree of visceral hypersensitivity among IBS 
patients as has been demonstrated in a recent Chinese study.90 An 
Indian study demonstrated induction of IBS symptoms following 
chili ingestion.99 A study from Thailand also showed that chili in-
gestion produced more abdominal pain and burning in IBS-D pa-
tients than in healthy volunteers.100 Several Japanese studies showed 
that patients with IBS showed greater colonic motor response than 
healthy controls to experimental stress, and suggested that cortico-
tropin releasing factor liberated from the hypothalamus to be the 
possible mediator.101,102
Statement 14: Some diarrhea-predominant IBS patients have 
been shown to have rapid GI transit, while some constipation-
predominant IBS is associated with slow transit.
Grade of evidence: high
 Level of agreement: a. 85.7%; b. 4.8%; c. 4.8%; d. 0.0%; e. 
0.0%; f. 4.8%
A few landmark studies showed that stool form is determined 
largely by colon transit time.19 A recent study, however, showed 
that the number of bacteria in the small bowel also determines stool 
forms; larger the number of bacteria in the small bowel, the looser 
the stools.64 Patients with IBS-D have shorter colonic transit time 
than those with IBS-C.103,104 Colonic transit time has been reported 
to be faster in Asian populations such as in India, Hong Kong, and 
Taiwan than in the West.105,106
Statement 15: IBS patients can show altered brain activations in 
specific regions, which might be involved in the perception of pain 
and emotional arousal.
Grade of evidence: low
 Level of agreement: a. 90.5%; b. 9.5%; c. 0.0%; d. 0.0%; e. 
0.0%; f. 0.0%
Like somatic sensation, visceral sensation including that from 
the gut is primarily presented to sensory cortex. However, visceral 
sensation can also lead to varying degree of emotional arousal due 
to activation of the emotional arousal system (limbic system and 
paralimbic structures), particularly among patients with IBS. Due 
to advances in functional imaging studies using functional magnetic 
resonance imaging (fMRI) and positron emission tomography 
(PET), understanding of cerebral processing of visceral sensation 
in patients with IBS as compared to healthy controls have been pos-
sible.
A few Asian studies showed that patients with IBS have exag-
gerated cerebral activation and abnormal emotional area activation 
following visceral and somatic stimulation, which is agreement with 
the Western studies. A Japanese study using PET showed that 
colonic distension resulted in enhanced activation of specific brain 
regions, including the limbic system and prefrontal cortex.107 An 
fMRI-based study from China showed that rectal balloon disten-
sion resulted in increased activity in the anterior cingulate cortex, 
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insula, prefrontal cortex, and thalamus, more so among IBS patients 
than controls.108 A study from Singapore showed abnormal cerebral 
activation on fMRI in anticipation of rectal pain among IBS pa-
tients during rectal stimulation.109 Cerebral and emotional response 
to pain is well known to differ among males and females. A recent 
Indian study on male IBS subjects and healthy controls showed 
differential brain response to rectal balloon distension and among 
patients with IBS-C and IBS-D.110
Statement 16: Psychosocial factors have significant role in the 
development and aggravation of IBS symptoms.
Grade of evidence: moderate
 Level of agreement: a. 80.9%; b. 14.3%; c. 4.8%; d. 0.0%; 
e. 0.0%; f. 0.0%
Several case-control studies both from the West and Asia 
showed that patients with IBS have more psychological co-morbid-
ities than healthy subjects.111 It is important, however, to note that a 
cause and effect relationship cannot be assigned based on such case-
control studies. Authors of a recent Australian study suggested that 
in most patients with functional GI disorders gut symptoms drives 
psychological morbidity rather than the brain being the primary ori-
gin of GI symptoms.59 However, studies on PI-IBS demonstrated 
that psychosocial co-morbidity are predictors of development of 
IBS following an episode of acute gastroenteritis.81 A Korean study 
showed that depressed women had greater severity of GI symptoms 
in relation to the degree of depression.112 Japanese studies also sug-
gested role of psychosocial stress exacerbating IBS symptoms.113
Some of the Asian data, like the Western studies, do suggest 
a role of psychosocial factors determining consultation behavior 
among patients with functional GI disorders including IBS. Anxi-
ety was the only independent predictor for medical consultation in 
a study from Hong Kong.114 In Pakistan, a high psychological dis-
tress score was a strong predictor of IBS in men, but not in women, 
while in India, there appeared to be more consulters in the higher 
socioeconomic classes.18,115 However, in Korea, India, and Japan, 
psychological factors appear to be less important to influence con-
sultation for IBS.18,116,117 These data may suggest that psychological 
co-morbidity may influence health care seeking in addition to socio-
cultural factors.
Statement 17: Genetic factors can contribute to the development 
of IBS, and gene–environmental interactions need to be further 
investigated.
Grade of evidence: low
 Level of agreement: a. 76.2%; b. 14.2%; c. 4.8%; d. 4.8%; 
e. 0.0%; f. 0.0%
It is well known that functional GI disorders, including IBS, 
occurs more often in families having members affected with these 
conditions. Though it has been argued that this may be related to 
environmental and socio-cultural factors, a role of genetic factors 
has also been considered. Polymorphisms in several genes involved 
inflammation, immune regulation, antigen recognition, defense 
mechanisms, tissue repair, neuro-transmission, lactose malabsorp-
tion etc have been studied in Asia.118 However, most of these stud-
ies suffer from limitation due to inadequate power resulting from 
relatively small sample size.
Team 3: Diagnosis and Investigations  
Statement 18: IBS is a condition characterized by recurrent 
abdominal pain/discomfort, occurring in association with defecation 
or a change in bowel habits, in the absence of organic causes that are 
detectable by routine medical tests.
Grade of evidence: low
 Level of agreement: a. 80.9%; b. 14.3%; c. 4.8%; d. 0.0%; 
e. 0.0%; f. 0.0%
The Rome IV criteria eliminated the term “discomfort” to 
reduce ambiguity and improve consistency of the criteria across 
different languages. The frequency of abdominal pain should be at 
least 1 day per week during the past 3 months with onset at least 6 
months earlier. In daily clinical practice, however, a pragmatic and 
flexible diagnostic approach should be adopted: pain is not universal 
in patients with IBS, who may have only abdominal discomfort or 
bloating as the predominant symptom, the threshold for symptom 
frequency and duration also needs validation in Asian countries.6,119
The BSFS is recommended as a reliable tool for evaluation 
of bowel habits. The subtyping of IBS is based on the stool con-
sistency on days with abnormal bowel habits when the patients are 
not taking any medication used for the treatment of the bowel habit 
abnormalities. Based on the BSFS, IBS can be classified into IBS-
D, IBS-C, mixed bowel habits, and unclassified. A recent study 
from Thailand suggested the BSFS type 3 is also associated with 
constipation. Thus, the correlation of BSFS with IBS classification 
in Asian patients may be different from that in the West. 120-122
Statement 19: The diagnosis of IBS requires careful history tak-
ing with reference to the diagnostic criteria of IBS, physical exami-
nation, and investigations may be performed if indicated, but there 
is no single diagnostic or confirmatory test for IBS.
Grade of evidence: low
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 Level of agreement: a. 85.7%; b. 4.8%; c. 4.8%; d. 4.8%; e. 
0.0%; f. 0.0%
For the majority of patients with IBS, a positive clinical diag-
nosis can be based on symptoms and physical examination, with 
limited investigations. Routine investigations are not warranted in 
all patients. However, a Canadian center analyzed the performance 
of symptom-based criteria in secondary-care centers and found a 
modest specificity of only 71-82% and positive predictive value of 
< 50%.123
Statement 20: Alarm features that needed to be excluded when 
considering the diagnosis of IBS include the presence of blood in 
the stools, unintended weight loss, anaemia, nocturnal symptoms, 
fever, abdominal mass, ascites, a family history of colorectal cancer, 
and age of onset > 50 years.
Grade of evidence: low
 Level of agreement: a. 76.2%; b. 14.3%; c. 9.5%; d. 0.0%; 
e. 0.0%; f. 0.0%
The presence of alarm features should prompt for investigations 
including colonoscopy, whereas the absence of alarm symptoms and 
negative physical examination are associated with lower likelihood 
of organic disease in patients with IBS symptoms.1 However, data 
to support this approach are weak.124,125
Statement 21: In the primary-care setting, a positive symptom-
based diagnosis of IBS is recommended to minimize unnecessary 
investigations. A step-wise approach, with special attention to the 
presence of alarm features and the judicious use of selected diagnos-
tic tests to rule out organic disease, is recommended.
Grade of evidence: low
 Level of agreement: a. 85.7%; b. 9.5%; c. 0.0%; d. 0.0%; e. 
0.0%; f. 4.8%
In the primary-care setting, selected non-invasive laboratory 
tests to exclude organic causes in patients without alarm features 
include full blood counts with erythrocyte sedimentation rate, blood 
chemistry with C-reactive protein, and stool examination for occult 
blood and fecal calprotectin.126-129 Normal C-reactive protein and 
fecal calprotectin in patients with non-constipation IBS can help 
exclude inflammatory bowel disease.130 Evidence to support this ap-
proach is however weak.7
Stool examination for intestinal parasites should be performed 
in countries with high prevalence of intestinal parasites. However, 
the association of intestinal parasites with symptoms of IBS is still 
controversial and limited.131
Statement 22: In the referral-center setting, recommended 
investigations include full blood counts, erythrocyte sedimentation 
rate, blood chemistry, C-reactive protein, thyroid function test, stool 
examination for occult blood, parasites and Clostridium difficile 
infection, and colonoscopy.
Grade of evidence: low
 Level of agreement: a. 66.6%; b. 23.8%; c. 4.8%; d. 0.0%; 
e. 0.0%; f. 4.8%
Colonoscopy for exclusion of colorectal cancer is indicated in 
patients with symptom onset at age 50 years or older, regardless of 
other alarm features. In younger patients, colonoscopy is indicated 
in the presence of alarm symptoms or signs, positive family history 
of colorectal cancer, and poor symptom response to empiric medical 
therapy.1,132 Patients included in clinical trials must have a colonos-
copy and/or other examinations as required by the entry criteria or 
study design.
Further work-up may be considered in selected patients for the 
diagnosis of other conditions such as SIBO, celiac disease, bile-acid 
diarrhea, malabsorption syndrome, and pancreatic or small bowel 
neoplasm. These investigations should be individualized according 
to the regional prevalence of each condition.64,85,133-135
Statement 23: Fecal evacuation disorder may present as consti-
pation-predominant IBS.
Grade of evidence: low
 Level of agreement: a. 85.7%; b. 4.8%; c. 4.8%; d. 4.8%; e. 
0.0%; f. 0.0%
Normal defecation requires coordination between contraction 
of the abdominal muscles that increase intra-rectal pressure and re-
laxation of the pelvic floor including the anal sphincter. Pubo-rectal 
dyssynergia is a common type of fecal evacuation disorder (FED). 
Different types of pubo-rectal dyssynergia are characterized by lack 
of increase in intra-rectal pressure or reduction in residual pressure 
in the anal canal during attempted defecation. An Indian study 
showed that the Rome III criteria for IBS were equally fulfilled 
among patients with constipation with or without FED.136 In a 
Thai study, of 50 patients with FED, 29 (58.0%) fulfilled Rome II 
criteria for IBS; patients with or without IBS demonstrated similar 
responses to biofeedback therapy.137 These Asian studies suggest 
that patients with FED may present as constipation-predominant 
IBS.138
Statement 24: Wheat sensitivity or non-celiac gluten sensitivity 
(NCGS) and IBS patients are distinct entities although their symp-
toms may overlap.
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Grade of evidence: moderate
 Level of agreement: a. 71.4%; b. 14.3%; c. 9.5%; d. 0.0%; 
e. 0.0%; f. 4.8%
NCGS is an increasingly recognized entity in the spectrum 
of gluten-related disorders, and is characterized by bowel symp-
toms similar to IBS. Evidence has emerged from several Asian 
countries for the presence of NCGS in patients fulfilling IBS crite-
ria.133-135,139,140 The pathophysiology of NCGS is poorly understood 
and a causal relationship between NCGS and IBS is still a subject 
of debate.141 Moreover, the symptom benefit obtained from a 
gluten-free diet may be attributed to its low fermentable oligo-, di-, 
monosacharides, and polyols (FODMAP) content.
Statement 25: In addition to symptom severity, evaluation of 
health-related quality of life (QOL), functional impairment, psy-
chological stressors and distress is recommended in the clinical eval-
uation of disease morbidity and monitoring of treatment response.
Grade of evidence: moderate
 Level of agreement: a. 85.7%; b. 0%; c. 14.3%; d. 0.0%; e. 
0.0%; f. 0.0%
IBS is associated with significant impairment in the QOL, so-
cial functioning, sleep, and psychological well-being.142-144 Validated 
questionnaires should be considered as supportive instruments for 
quantitative and objective assessment of quality-of-life impairment 
and psychological distress. Short form 36, EuroQol 5 dimension, 
Hospital Anxiety and Depression Scale, Patient Health Question-
naire, and IBS-QOL have been used in Asian studies.
Team 4: Life Style Modifications and Treat-
ments  
Introduction/General Comments
In the first Asian IBS consensus,1 it was generally agreed that 
the aims of IBS management are symptom relief as well as improv-
ing QOL, with the establishing of a good doctor–patient relation-
ship being a cornerstone. Physicians were recommended to identify 
contributing factors and the patient’s specific concerns, so that the 
management of IBS may be individualized. Specifically, all bother-
some symptoms should be targeted, taking into account specific 
IBS subtypes, symptom severity, and contributing factors including 
psychosocial issues. It was generally agreed that these remain fun-
damental to effective management of IBS. Since the last iteration, 
there has been substantial new information in dietary and pharma-
cological management.145
Statement 26: A low FODMAPs diet could be helpful in IBS.
Grade of evidence: moderate
 Level of agreement: a. 85.7%; b. 4.8%; c. 9.5%; d. 0.0%; e. 
0.0%; f. 0.0%
As diet is a frequent concern, a detailed dietary history was 
commended. New data involving diets in Western populations sug-
gest that a diet low in FODMAPs may be effective in improving 
bloating, flatulence, and abdominal pain.146,147 As these are non-
absorbable sugars, they are osmotically active, and subjected to 
fermentation in the colon, resulting in the production of metabolites 
and gases, that may contribute to causing diarrhea, abdominal pain, 
and bloating. Patients of all IBS subtypes had greater satisfaction 
with stool consistency while on the low-FODMAPs diet, while 
diarrhea-predominant IBS appeared to benefit from improved stool 
consistency and frequency.147 Specifically to Asian populations, the 
role of a low FODMAPs diet in the management of IBS requires 
further study as studies are lacking.148,149 While in some communi-
ties (eg, India with high prevalence of vegetarianism) diets may be 
high in FODMAPs, others may traditionally be relatively low (eg, 
China and Japan).48,148,149 Lactose as a FODMAP is of specific 
relevance to Asia as lactase deficiency is almost universal in Asians. 
88,150  However, as the average daily consumption is relatively low, 
the role of lactose-containing dairy foods in Asia is uncertain. 48,151 
Statement 27: Antispasmodic agents are efficacious for the 
treatment of abdominal pain in IBS.
Grade of evidence: high
 Level of agreement: a. 85.7%; b. 14.3%; c. 0.0%; d. 0.0%; 
e. 0.0%; f. 0.0%
Meta-analysis of antispasmodics as well as several Asian clinical 
trials support the efficacy of this class of drugs to relief IBS symp-
toms, especially when abdominal pain is the predominant symp-
tom.145,152-157  As a class, anti-spasmodics have a favorable profile 
with number needed to treat (NNT) of 5 and number needed to 
harm of 17.5.152 However, some antispasmodics may have anticho-
linergic side effects.
Statement 28: Antidiarrheal agents are effective in controlling 
diarrhea in IBS.
Grade of evidence: moderate
 Level of agreement: a. 76.2%; b. 14.3%; c. 9.5%; d. 0.0%; 
e. 0.0%; f. 0.0%
Common antidiarrheal agents studied for the treatment of IBS 
were loperamide and smectite. Loperamide is an opioid agonist 
that is frequently used to control diarrhea both in infectious and 
352
Kok Ann Gwee, et al
Journal of Neurogastroenterology and Motility 
non-infectious conditions. A limited number of randomized con-
trol trials (RCTs) are available that support its efficacy in IBS, and 
confidence in the estimate of effect was further limited by the small 
sample sizes.158-160 Data on the use in IBS of natural adsorbent clay 
compounds such as dioctahedral smectite that is frequently used 
to treat diarrhea in children, is very limited and suggests effect on 
abdominal discomfort or bloating.161,162
Statement 29: Some 5-HT3 antagonists are effective in IBS-D.
Grade of evidence: high
 Level of agreement: a. 80.9%; b. 14.3%; c. 4.8%; d. 0.0%; 
e. 0.0%; f. 0.0%
Serotonin is a neurotransmitter functioning in GI sensation, 
motility, and secretion. In the GI tract, 5-HT receptor subtype 3 
and 4 mediate key functions that have been targeted for ameliora-
tion of IBS symptoms.163 5-HT3 antagonists have been shown to 
slow intestinal transit and to decrease abdominal pain.164,165 Ex-
amples of 5-HT3 antagonists that have been tested in IBS are alos-
etron, ramosetron, and ondansetron. Alosetron encountered serious 
side effect of ischemic colitis and is now available only in the USA. 
Ramosetron was newly developed in Japan for the treatment of 
IBS-D. In a trial comparing ramosetron with placebo, patients with 
IBS-D treated with ramosetron showed significant improvements 
in global IBS symptoms, abdominal pain, and bowel habits.166 A 
Japanese study for the effect of ramosetron on IBS-D patients also 
showed significantly increased rate of symptom improvements in 
ramosetron group (47.0%) than placebo group (27.0%).167 In a re-
cent randomized, placebo-controlled study of 576 Japanese women 
with IBS-D, 2.5 μg ramosetron per day reduced abdominal pain 
and discomfort, increased stool consistency, and improved QOL as 
well as global IBS symptoms.168
Although in these studies, there have not been any reports 
regarding significant adverse reactions including ischemic colitis 
to this drug, significant proportions of 1 in 5 reported constipation 
after treatment of ramosetron.166-168 Ramosetron is also approved for 
managing patients with IBS-D in Japan, Korea, and Thailand.169 
Ondansetron is an established anti-emetic with good safety record. 
In an investigator initiated RCT from the UK, a pragmatic ap-
proach was employed whereby starting at 4 mg once a day, the dose 
could be titrated up to 8 mg 3 times a day, ondansetron was found 
to be more effective than placebo in improving loose stools, bowel 
frequency and urgency.170
Statement 30: Some serotonin 5-HT4 receptor agonists are ef-
fective in constipation-predominant IBS.
Grade of evidence: high
 Level of agreement: a. 85.7%; b. 9.5%; c. 4.8%; d. 0.0%; e. 
0.0%; f. 0.0%
Tegaserod is a partial 5-HT4 agonist with high quality data 
from Asia for efficacy in IBS-C, both in women and men.171-173 Un-
fortunately, a controversial alert by Food and Drug Administration 
regarding cardiovascular safety has led to its withdrawal from most 
countries.174 An alternative, prucalopride is a selective 5-HT4 ago-
nist, that has high quality efficacy data for relieving bloating, hard 
stool, and straining, symptoms commonly associated with IBS-
C.175-179 While prominent side effects include diarrhea, headache, 
abdominal pain, and nausea, no cardiovascular safety concerns have 
been reported.174,177 Studies involving tegaserod and prucalopride, 
including 3 involving Asian subjects, provide evidence of efficacy in 
male subjects.173,178,179
Statement 31: The effectiveness of probiotics has not been fully 
validated in IBS.
Grade of evidence: moderate
 Level of agreement: a. 85.7%; b. 4.8%; c. 9.5%; d. 0.0%; e. 
0.0%; f. 0.0%
Probiotics are live micro-organisms that confer health benefits. 
Several meta-analysis provide evidence that some probiotics have 
beneficial effect in IBS, but not all probiotics have demonstrated 
benefit.180 Thus, which species or combination was the most benefi-
cial is unclear. Where a beneficial effect has been demonstrated, im-
provements in abdominal pain, bloating, and flatulence have been 
reported.
It is specifically noted that these meta-analyses were carried 
out on heterogeneous studies. While Lactobacillus rhamnosus 
GG has strong evidence in children, this was lacking in adult IBS 
patients.181,182 In a study of adult IBS patients, Bifidobacterium 
infantis was found to improve symptoms over placebo, whereas 
Lactobacillus salivarius did not.183 In a related study from the same 
investigators treatment with the same strain produced significant 
improvement of IBS symptoms only for intermediate dose.184,185 
The authors emphasized the need for clinical data in the final dos-
age form and dose of a probiotic before confirming efficacy in clini-
cal use. This was endorsed and emphasized in a recently published 
Asian consensus on probiotics.185
Statement 32: Antidepressants are effective for IBS, but it is 
unclear which patient will benefit.
Grade of evidence: moderate
 Level of agreement: a. 71.4%; b. 14.3%; c. 14.3%; d. 0.0%; 
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e. 0.0%; f. 0.0%
A meta-analysis of 16 RCTs, found RR of IBS symptom not 
improving with antidepressants vs placebo was 0.67 and NNT 
of 4.186 The quality of the data appeared to be better for tricyclic 
antidepressant (TCA) than selective serotonin reuptake inhibitor 
(SSRI). Doses of TCA used in IBS trials were frequently below 
therapeutic range for depression; in particular, 3 Asian studies used 
low doses of TCAs.187-189 This suggests the possibility of a peripher-
al effect. On the other hand, doses of SSRIs used in IBS especially 
the studies from the West, were at anti-depressant levels.190,191 In one 
RCT of citalopram where non-depressed patients were excluded, 
there was no evidence of benefit.190 This suggests that SSRI may 
be acting at the central level. It should be noted that these agents 
are only used off label in many countries, and it is important to be 
familiar with known side-effects.
Statement 33: Secretagogues are effective in IBS-C.
Grade of evidence: high
 Level of agreement: a. 85.7%; b. 14.3%; c. 0.0%; d. 0.0%; 
e. 0.0%; f. 0.0%
Linaclotide, a guanylate cyclase-C agonist, with very low oral 
bioavailability, acts locally in the intestinal tract to stimulate fluid se-
cretion, increase colonic transit, and inhibit colonic nociceptors.192-194 
In Asia, a recent study with linaclotide 290 mg, involving close to 
700 patients from China, found significant efficacy over placebo for 
abdominal pain (60.0% vs 49.0%) and diarrhea was the commonest 
side effect (9.0%).195 This reinforces the findings of 2 pivotal studies 
where abdominal pain endpoints were met by about 54.0% on lina-
clotide vs 36.0-42.0% on placebo.196-198 Similarly, the commonest 
adverse event of linaclotide was diarrhea (19.7%).199
Lubiprostone is a luminally acting prostone that selectively 
activates the type-2 chloride ion channel (ClC-2 chloride channel) 
expressed in the small intestinal epithelial cells, thereby increas-
ing the amount of water content it the intestinal lumen.200 In Asia, 
efficacy of lubiprostone for IBS-C has been evaluated in only 42 
patients in a Japanese study with only the 48 mg dose showing su-
periority over placebo.201 Initial dose ranging studies had found that 
the 48 mg dose was associated with more GI adverse events than 
the 16 mg dose which was considered the optimal dose for efficacy 
and safety.202 Nausea was the commonest side effect, occurring in 
as many as 31%, and is dose dependent.203 Furthermore, long-term 
safety data is available only for the 16 mg dose, but not for the 48 mg 
dose.204 A recent systematic review and meta-analysis observed that 
while lubiprostone was efficacious in the short term, and except for 
bloating all other outcomes including abdominal pain did not ap-
pear to be different from placebo.205
Statement 34: Non-absorbable antibiotics are effective in IBS.
Grade of evidence: high
 Level of agreement: a. 47.6%; b. 42.9%; c. 9.5%; d. 0.0%; 
e. 0.0%; f. 0.0%
Rifaximin is a rifamycin derived non-absorbable antibiotic 
which is associated with anti-inflammatory activity. Meta-analysis 
involving 5 high quality studies, found efficacy for global IBS 
symptoms, with secondary outcome analysis indicating that bloat-
ing could be the key symptom responding to rifaximin in non-
constipated IBS.206 Adverse effects were similar among patients re-
ceiving rifaximin or placebo in all studies.207 Repeat treatments with 
rifaximin also appear to be safe.208,209 While the role of antibiotics 
was premised on the presence of low-grade SIBO, none of the piv-
otal studies actually evaluated this. One study from China reported 
that identifying SIBO among patients with IBS criteria produced 
better outcome.210 A study from India employing norfloxacin simi-
larly observed better response in those with demonstrable SIBO.66 
However, data on the efficacy of rifaximin for IBS in Asia are lack-
ing. One study from Hong Kong found that a 2-week course pro-
duced significant relief of symptoms in functional dyspepsia, but in 
this study, patients with overlapping IBS were actively excluded. 211
Statement 35: Some complementary and alternative medicine 
(CAM) (specifically peppermint oil and Kampo) could be effective 
in treating IBS.
Grade of evidence: low
 Level of agreement: a. 71.4%; b. 14.3%; c. 9.5%; d. 0.0%; 
e. 0.0%; f. 4.8%
Its heterogeneity makes it difficult to evaluate the efficacy of 
CAM as a single treatment class. The 4 commonest CAM treat-
ments were evaluated. Chinese herbal medicine has the biggest 
evidence base and will be evaluated separately. Peppermint oil, 
thought to alleviate IBS symptoms by relaxing smooth muscles via 
calcium channels, has been shown in a meta-analysis to be effica-
cious for IBS.152 A review of Japanese herbal medicine (Kampo) 
found little clinical trial evidence for a role in IBS.212 Daikenchuto 
was reported to reduce symptoms of constipation in children, while 
Hangeshasin-to was reported to have anti-diarrheal effect in drug-
induced diarrhea. Two single-blind clinical trials involving a total of 
273 subjects found no difference between acupuncture and sham 
acupuncture.213,214
Statement 36: Traditional Chinese medicines including herbal 
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and patent prescriptions could be helpful for some IBS patients, but 
the efficacies should be validated with high quality RCT.
Grade of evidence: moderate
 Level of agreement: a. 76.2%; b. 9.5%; c. 9.5%; d. 0.0%; e. 
0.0%; f. 4.8%
A meta-analysis of 14 RCTs of Chinese herbal medicines, 
involving 1551 subjects with IBS-D, found efficacy for global 
IBS symptoms, abdominal pain and diarrhea, but recognized that 
there was high heterogeneity and study sample sizes were gener-
ally small.215 One formulation known as Shugan Jianpi Zhixie had 
7 trials of 954 IBS-D patients.216 Another formulation known as 
Tongxie Yaofang had 23 publications involving 1972 IBS-D pa-
tients.217 A very recently published RCT had 1044 patients with 
Rome III criteria IBS randomized to 3 treatments for 4 weeks, and 
found that Tongxie Yaofang was significantly better than placebo for 
improving abdominal pain and stool parameters, but not better than 
pinaverium for abdominal pain.218
Statement 37: Psychotherapy is possibly useful in IBS, but data 
only supports its use in tertiary care patients.
Grade of evidence: low
 Level of agreement: a. 90.5%; b. 9.5%; c. 0.0%; d. 0.0%; e. 
0.0%; f. 0.0%
A meta-analysis of 41 RCTs of psychotherapy for adults with 
IBS, found that none of the trials were at low risk of bias for every 
domain.219 The majority of studies were from USA, Sweden, and 
UK. On review of the demographic characteristics of study partici-
pants, it was acknowledged that the majority of patients were white 
and female. Asian experience with psychotherapy is limited to only 
one study each from Korea220 and from Japan.221 The Korean study 
employed cognitive behavioral therapy and recruited only female 
nursing students.220 This limits the generalizability of the outcome 
as the expectation is that these subjects were young and familiar 
with clinical science. The Japanese study employed autogenic train-
ing as a relaxation technique.221 The sample size was small (10 male 
and 11 female) and subjects were recruited from a psychosomatic 
department. Thus, the acceptance and understanding of this tech-
nique by a broader group of IBS subjects are unknown.
Another meta-analysis of 36 RCTs involving a variety of psy-
chotherapies (including cognitive behavioral therapy, relaxation 
therapy, hypnotherapy, dynamic psychotherapy and mindfulness) 
involving a total of 2189 patients found that overall IBS symptoms 
did not improve in 52% compared with 76% receiving control in 
the form of symptom monitoring, physician’s usual management, 
supportive therapy or placebo.186 There were serious issues regard-
ing the validity of the findings as none of the trials were at low risk 
of bias, 22 (61.0%) studies were based in tertiary care setting, 30 
(83.0%) studies were unblinded and concealment of allocation 
was not stated in 24 (67.0%) studies. It remains unclear whether 
psychotherapy is effective for the treatment of IBS in primary care, 
with only 2 of the RCTs conducted entirely within this setting.222 A 
further concern was that 9 of the eligible studies originated from the 
same center, and when a subgroup analysis was conducted examin-
ing this issue there appeared to be a greater treatment effect in these 
9 studies than in the 11 studies emanating from other centers.
A number of weaknesses common to several RCTs of psycho-
logical therapies were their failure to use the Rome criteria, absence 
of a power calculation, use of non-validated outcome measures, and 
inadequate blinding.222 Furthermore, the effect of psychotherapy on 
IBS symptoms in the long term remains unknown.219,222,223
Conclusions  
Our consensus sought to represent current knowledge in a way 
that will be clinically useful to doctors treating IBS in Asia. The first 
and rate-limiting step in its management is to be able to make an 
early and confident diagnosis of IBS. Thus, it is important that phy-
sicians in Asia are able to recognize IBS based on the Asian experi-
ence, rather than parameters set by the West. In a landmark pan-
Asian study, the pattern of symptom clusters in FGID patients was 
found to be quite different from the classification system proposed 
by the Rome committee.224 A greater emphasis was placed on meal-
related symptoms by Asian patients with IBS criteria. In fact, sub-
sequent reports from Australia and from a Rome Foundation study 
group also found that there are important issues with the Rome IV 
criteria.225,226 Future research in Asia should test the Asian symptom 
clusters against the Rome-proposed symptom clusters. We should 
also test whether socio-cultural and environmental factors influence 
the greater overlap between IBS and upper GI symptoms in Asia, 
and whether this makes it more challenging to recognize IBS here.
Asian data substantiate the global research that now places IBS 
as a disorder of gut-brain interaction, recognizing the key role of the 
intestinal micro-environment. Previous emphasis on the psychologi-
cal disturbance could have contributed to a lack of interest in IBS 
within the GI community in Asia. The emergence of more effective 
treatments with peripheral targets should encourage greater effort 
to recognize IBS in our patients. Furthermore, our rich heritage of 
traditional Asian treatments, together with emerging data on the 
potential of herbal medicines, earmarks this as an important field of 
exploration for future treatments. All patients with IBS should be 
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evaluated comprehensively with a view to holistic management.
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